Oncolytics Biotech, Inc.

Innately Adaptive™

Oncolytics Biotech Inc. is developing REOLYSIN®, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that targets cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological malignancies.

What is Immuno-Oncology?

What is Immuno-Oncology?

Immuno-oncology is a unique medical approach to treating cancer that utilizes the body's own immune system to fight off cancer cells.

How We're Developing REOLYSIN® as an
Immuno-Oncology Agent

Our Focus

We’re committed to developing REOLYSIN® into an effective treatment that can be combined with multiple therapies in order to boost its mechanism of action response.

Program 1: <br>Chemo combinations

Program 1:
Chemo combinations

Taking advantage of stressed tumor cells to initiate cell lysis.

Program 2: <br>Immunomodulator (IMiDs) / targeted therapy combinations

Program 2:
Immunomodulator (IMiDs) / targeted therapy combinations

REOLYSIN® is currently being studied in combination with Celgene's Imnovid® & Revlimid® in a first-of-its-kind immunotherapy trial that aims to modulate the immune system to target myeloma.

Program 3: <br> Immunotherapy combinations

Program 3:
Immunotherapy combinations

An approach, and collaboration opportunity, where REOLYSIN® is combined with immunotherapies (such as with Keytruda in the REO 024 study).

Latest News

May 17, 2018

Oncolytics Biotech® Announces Collaboration Between Merck and Northwestern University Combining Keytruda® and REOLYSIN® in a Phase 2 Second Line Pancreatic Cancer Study

May 16, 2018

Oncolytics Biotech® Announces Publication of REOLYSIN® Abstract for the ASCO 2018 Annual Meeting

May 11, 2018

Oncolytics Biotech® Reports 2018 First Quarter Results

View All News

Corporate Presentation

Corporate Presentation